342 related articles for article (PubMed ID: 8558221)
21. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
Valero V
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.
Seidman AD; Tiersten A; Hudis C; Gollub M; Barrett S; Yao TJ; Lepore J; Gilewski T; Currie V; Crown J
J Clin Oncol; 1995 Oct; 13(10):2575-81. PubMed ID: 7595709
[TBL] [Abstract][Full Text] [Related]
23. Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study.
Ferraresi V; Milella M; Vaccaro A; D'Ottavio AM; Papaldo P; Nisticò C; Thorel MF; Marsella A; Carpino A; Giannarelli D; Terzoli E; Cognetti F
Am J Clin Oncol; 2000 Apr; 23(2):132-9. PubMed ID: 10776972
[TBL] [Abstract][Full Text] [Related]
24. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC.
Fumoleau P; Chevallier B; Kerbrat P; Krakowski Y; Misset JL; Maugard-Louboutin C; Dieras V; Azli N; Bougon N; Riva A; Roche H
Ann Oncol; 1996 Feb; 7(2):165-71. PubMed ID: 8777173
[TBL] [Abstract][Full Text] [Related]
25. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer.
van Oosterom AT
Semin Oncol; 1995 Dec; 22(6 Suppl 13):22-8. PubMed ID: 8604449
[TBL] [Abstract][Full Text] [Related]
26. Premedication strategy for weekly paclitaxel.
Quock J; Dea G; Tanaka M; Gandara D; Lara P; Lau D
Cancer Invest; 2002; 20(5-6):666-72. PubMed ID: 12197222
[TBL] [Abstract][Full Text] [Related]
27. Future perspectives of docetaxel (Taxotere) in front-line therapy.
Piccart MJ; Di Leo A
Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-27-S10-33. PubMed ID: 9275004
[TBL] [Abstract][Full Text] [Related]
28. Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions.
Sasada S; Hirashima T; Nakamura Y; Takimoto T; Furukawa M; Kobayashi M; Nitta T; Matsui K; Kawase I
Int J Clin Oncol; 2007 Aug; 12(4):274-8. PubMed ID: 17701006
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma.
Pazdur R; Lassere Y; Soh LT; Ajani JA; Bready B; Soo E; Sugarman S; Patt Y; Abbruzzese JL; Levin B
Ann Oncol; 1994 May; 5(5):468-70. PubMed ID: 7915537
[TBL] [Abstract][Full Text] [Related]
30. Risks and benefits of taxanes in breast and ovarian cancer.
Michaud LB; Valero V; Hortobagyi G
Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
[TBL] [Abstract][Full Text] [Related]
31. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.
Reichman BS; Seidman AD; Crown JP; Heelan R; Hakes TB; Lebwohl DE; Gilewski TA; Surbone A; Currie V; Hudis CA
J Clin Oncol; 1993 Oct; 11(10):1943-51. PubMed ID: 7691998
[TBL] [Abstract][Full Text] [Related]
32. Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trial.
Schmidinger M; Budinsky AC; Wenzel C; Locker GJ; Pluschnig U; Brodowicz T; Kubista E; Maca S; Zabernigg A; Ilsinger P; Seewann L; Hojas S; Blach M; Zielinski CC; Steger GG
Cancer Chemother Pharmacol; 2001; 47(1):57-62. PubMed ID: 11221963
[TBL] [Abstract][Full Text] [Related]
33. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group.
ten Bokkel Huinink WW; Prove AM; Piccart M; Steward W; Tursz T; Wanders J; Franklin H; Clavel M; Verweij J; Alakl M
Ann Oncol; 1994 Jul; 5(6):527-32. PubMed ID: 7918124
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.
Zalcberg J; Millward M; Bishop J; McKeage M; Zimet A; Toner G; Friedlander M; Barter C; Rischin D; Loret C; James R; Bougan N; Berille J
J Clin Oncol; 1998 May; 16(5):1948-53. PubMed ID: 9586914
[TBL] [Abstract][Full Text] [Related]
35. Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy.
Valero V
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-11-S13-18. PubMed ID: 9335512
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.
Fossella FV; Lee JS; Murphy WK; Lippman SM; Calayag M; Pang A; Chasen M; Shin DM; Glisson B; Benner S
J Clin Oncol; 1994 Jun; 12(6):1238-44. PubMed ID: 7911160
[TBL] [Abstract][Full Text] [Related]
37. Docetaxel (Taxotere) in combination: a step forward.
Burris HA; Fields S; Peacock N
Semin Oncol; 1995 Dec; 22(6 Suppl 13):35-40. PubMed ID: 8604452
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group.
Forsyth P; Cairncross G; Stewart D; Goodyear M; Wainman N; Eisenhauer E
Invest New Drugs; 1996; 14(2):203-6. PubMed ID: 8913841
[TBL] [Abstract][Full Text] [Related]
39. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
D'Andrea G; Fennelly D; Norton L; Baselga J; Gilewski T; Hudis C; Moynahan ME; Raptis G; Sklarin N; Surbone A; Theodoulou M; Templeton MA; Yao TJ; Seidman AD
Clin Cancer Res; 1999 Feb; 5(2):275-9. PubMed ID: 10037175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]